文献速递胸部肿瘤

IMpower150最终总生存分析:阿替利珠单抗联合贝伐珠单抗及化疗一线治疗转移性非鳞NSCLC

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-07-24

IMpower150研究最终总生存分析显示,在化疗初治的转移性非鳞NSCLC患者中,阿替利珠单抗+卡铂+紫杉醇(ACP)相比贝伐珠单抗+卡铂+紫杉醇(BCP)的OS改善未达统计学显著(ITT-WT:19.0 vs 14.7个月,HR=0.84,95%CI 0.71-1.00)。阿替利珠单抗+贝伐珠单抗+卡铂+紫杉醇(ABCP)相比BCP持续显示OS获益(ITT-WT:19.5 vs 14.7个月,HR=0.80,95%CI 0.67-0.95)。

要点

  • ACP相比BCP在ITT-WT人群的OS改善为数值上但未达统计学显著。
  • ABCP相比BCP在ITT-WT人群持续显示OS获益,中位OS 19.5 vs 14.7个月。
  • 探索性分析显示PD-L1高表达和阳性亚组中ABCP和ACP相比BCP中位OS更长。

核心结论

  • ACP相比BCP的OS改善为数值上但未达统计学显著(ITT-WT:19.0 vs 14.7个月,HR=0.84,95%CI 0.71-1.00)。
  • ABCP相比BCP在ITT-WT人群持续显示OS获益(19.5 vs 14.7个月,HR=0.80,95%CI 0.67-0.95)。

研究设计与样本

  • III期随机开放标签IMpower150研究(NCT02366143),纳入1202例化疗初治的转移性非鳞NSCLC患者。
  • 共同主要终点为ITT野生型(无EGFR或ALK改变)人群的研究者评估PFS和OS。

主要发现

  • ACP vs BCP最终分析(数据截止2019年9月13日,最小随访32.4个月)ITT-WT中位OS 19.0 vs 14.7个月,HR=0.84(95%CI 0.71-1.00)。
  • ABCP vs BCP在ITT-WT中位OS 19.5 vs 14.7个月,HR=0.80(95%CI 0.67-0.95)。
  • 探索性分析中,SP142定义的PD-L1高表达和阳性亚组,ABCP和ACP相比BCP中位OS更长;PD-L1阴性亚组中ACP和ABCP与BCP的中位OS相似。
  • 安全性与此前分析(数据截止2018年1月22日)一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months of median follow-up with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP) in chemotherapy-naive patients with metastatic nonsquamous NSCLC in the phase 3 IMpower150 study (NCT02366143). METHODS: In this randomized, open-label study (N = 1202), coprimary end points included investigator-assessed progression-free survival and OS in intention-to-treat (ITT) wild-type (WT; no EGFR or ALK alterations) patients. Secondary and exploratory end points included OS in ITT and programmed death-ligand 1 (PD-L1) subgroups defined by the VENTANA SP142 and SP263 immunohistochemistry assays. RESULTS: At the final analysis with ACP versus BCP (data cutoff: September 13, 2019; minimum follow-up: 32.4 mo), ACP had numerical, but not statistically significant, improvements in OS (ITT-WT: median OS = 19.0 versus 14.7 mo; hazard ratio = 0.84; 95% confidence interval: 0.71-1.00). OS benefit was sustained with ABCP versus BCP (ITT-WT: 19.5 versus 14.7 mo; hazard ratio = 0.80; 95% confidence interval: 0.67-0.95). Exploratory analyses in the SP142-defined PD-L1 subgroups revealed longer median OS with ABCP and ACP versus BCP in PD-L1-high and PD-L1-positive subgroups; in the PD-L1-negative subgroups, median OS was similar with ACP and ABCP versus BCP. Safety was consistent with that in earlier analyses (data cutoff: January 22, 2018). CONCLUSIONS: At the final IMpower150 OS analysis, ACP had numerical, but not statistically significant, OS improvement versus BCP. Updated data with an additional 20 months of follow-up revealed continued OS improvement with ABCP versus BCP in all patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021. PMID: 34311108. doi:10.1016/j.jtho.2021.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。